#cirrhosis

People with advanced fibrosis—not just cirrhosis—were at greater risk for hepatocellular carcinoma.

People who are living with all three viruses have a greater likelihood of progressing to end-stage liver disease.

Risk-based testing alone has failed to identify a majority of people living with chronic HBV.

Successful antiviral treatment partially turns back the clock on age acceleration.

Most outcomes were similar in lean and heavy people with fatty liver disease, but the lean group had higher liver-related mortality.

Better results were observed even in people with increased portal hypertension.

Advocates are working to deliver medication directly to patients to combat this alarming decrease in care.

Some 20% of those with NAFLD also showed signs of liver fibrosis.

People treated with direct-acting antivirals had a lower risk for liver failure and liver cancer as well as much lower mortality.

Experts predict that more than a million people could die from liver cancer worldwide in 2040.

Even though as many as 97% of patients can be cured with medication, many still don’t receive the treatment.

Black people make up only 6% and Latino people make up 5% of participants in cirrhosis trials in the United States.

People who achieved SVR two or more years ago were less likely to develop hepatocellular carcinoma than those cured more recently.

Diabetes and a large waist circumference are predictors of liver fat accumulation and fibrosis.

People with a tendency to be active later in the day may be at greater risk for severe NAFLD.

The antiviral treatment is safe and effective for pediatric patients ages 12 and up.